Development of sarcoidosis during treatment for chronic hepatitis C with pegylated interferon alfa-2a and ribavirin : case report and literature review
Sarcoidosis is a chronic inflammatory multisystem disease of unknown aetiology. IFN-alfa is an immunomodulatory cytokine, currently used with ribavirin in the treatment of chronic hepatitis C infection. Due to its effects on the immune system, IFN-? may lead to the induction or exacerbation of autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis and sarcoidosis. We report on a 37-year-old man, presenting with sarcoidosis during a six-month course of PEG-IFN alfa-2a and ribavirin for chronic hepatitis C virus genotype 3 infection.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2013 |
---|---|
Erschienen: |
2013 |
Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
---|---|
Enthalten in: |
Le infezioni in medicina - 21(2013), 1 vom: 09. März, Seite 40-44 |
Sprache: |
Italienisch |
---|
Weiterer Titel: |
Un caso di sarcoidosi associata al trattamento con PEG-IFN α-2a e ribavirina in un paziente affetto da epatite cronica HCV correlata: caso clinico e revisione della letteratura |
---|
Beteiligte Personen: |
Cacopardo, Bruno [VerfasserIn] |
---|
Anmerkungen: |
Date Completed 28.01.2014 Date Revised 16.08.2019 published: Print Citation Status MEDLINE |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
NLM226090612 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM226090612 | ||
003 | DE-627 | ||
005 | 20231224070639.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231224s2013 xx |||||o 00| ||ita c | ||
028 | 5 | 2 | |a pubmed24n0753.xml |
035 | |a (DE-627)NLM226090612 | ||
035 | |a (NLM)23524900 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a ita | ||
100 | 1 | |a Cacopardo, Bruno |e verfasserin |4 aut | |
245 | 1 | 0 | |a Development of sarcoidosis during treatment for chronic hepatitis C with pegylated interferon alfa-2a and ribavirin |b case report and literature review |
246 | 3 | 3 | |a Un caso di sarcoidosi associata al trattamento con PEG-IFN α-2a e ribavirina in un paziente affetto da epatite cronica HCV correlata: caso clinico e revisione della letteratura |
264 | 1 | |c 2013 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 28.01.2014 | ||
500 | |a Date Revised 16.08.2019 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Sarcoidosis is a chronic inflammatory multisystem disease of unknown aetiology. IFN-alfa is an immunomodulatory cytokine, currently used with ribavirin in the treatment of chronic hepatitis C infection. Due to its effects on the immune system, IFN-? may lead to the induction or exacerbation of autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis and sarcoidosis. We report on a 37-year-old man, presenting with sarcoidosis during a six-month course of PEG-IFN alfa-2a and ribavirin for chronic hepatitis C virus genotype 3 infection | ||
650 | 4 | |a Case Reports | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 7 | |a Antiviral Agents |2 NLM | |
650 | 7 | |a Glucocorticoids |2 NLM | |
650 | 7 | |a Interferon-alpha |2 NLM | |
650 | 7 | |a Recombinant Proteins |2 NLM | |
650 | 7 | |a Polyethylene Glycols |2 NLM | |
650 | 7 | |a 3WJQ0SDW1A |2 NLM | |
650 | 7 | |a Ribavirin |2 NLM | |
650 | 7 | |a 49717AWG6K |2 NLM | |
650 | 7 | |a peginterferon alfa-2a |2 NLM | |
650 | 7 | |a Q46947FE7K |2 NLM | |
650 | 7 | |a Prednisone |2 NLM | |
650 | 7 | |a VB0R961HZT |2 NLM | |
700 | 1 | |a Pinzone, Marilia Rita |e verfasserin |4 aut | |
700 | 1 | |a Nunnari, Giuseppe |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Le infezioni in medicina |d 1995 |g 21(2013), 1 vom: 09. März, Seite 40-44 |w (DE-627)NLM095542906 |x 2532-8689 |7 nnns |
773 | 1 | 8 | |g volume:21 |g year:2013 |g number:1 |g day:09 |g month:03 |g pages:40-44 |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 21 |j 2013 |e 1 |b 09 |c 03 |h 40-44 |